• Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm

    8 days ago - By Business Insider

    Biogen. Budrul Chukrut/SOPA Images/LightRocket via Getty Images
    Biogen stock dropped 10% early Wednesday after Medicare said it would limit coverage of the company's Alzheimer's disease drug.
    Medicare will only cover patients who are enrolled in clinical trials evaluating Aduhelm, a drug that costs $28,000 a year.
    Biogen urged Medicare to grant broader access to Aduhelm in its final decision due in April.
    Sign up here for our daily newsletter, 10 Things Before the Opening Bell .
    Investors knocked Biogen stock down by more than 10% early Wednesday after the US Centers for Medicare and...
    Read more ...

     

  • Biogen tumbles after Medicare lays out Aduhelm coverage plan

    8 days ago - By Chron

    Shares of Biogen started sliding early Wednesday, a day after federal regulators slapped strict limitations on coverage the drugmaker's new Alzheimer's disease treatment.
    The Centers for Medicare and Medicaid Services said Tuesday after markets closed that patients taking Biogen's Aduhelm will have to also participate in clinical trials to assess the drug's effectiveness in order for Medicare to cover the cost.
    That's an important caveat because Medicare is expected to cover most of the patients who opt for Aduhelm, and the drug can cost as much as $28,000 annually, not counting expenses...
    Read more ...

     

  • Piper Sandler downgrades Biogen as Alzheimer's drug hits another speedbump

    9 days ago - By CNBC

    Medicare on Tuesday said it would limit coverage of Biogen's Aduhelm medication only to patients who are willing to enroll in qualifying clinical trials.
    Read more ...